drugset / Trial / NCT02343718
Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the best dose of vinblastine that can be given with a new drug, temsirolimus.
Timeline
- Start
- 2015-06-24
- Primary completion
- 2017-09-28
- Completion
- 2019-01-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Temsirolimus | Small molecule | 0.5 mg/kg | Intravenous |
| Subject | Temsirolimus | Small molecule | 10 mg/m2 | Intravenous |
| Subject | Temsirolimus | Small molecule | 15 mg/m2 | Intravenous |
| Subject | Vinblastine | Small molecule | 0.13 mg/kg | Intravenous |
| Subject | Vinblastine | Small molecule | 4 mg/m2 | Intravenous |